Nice Try Bill! The Chinese Communist Party stepping in on compromised China C.D.C. Director ‘George Fu Gao’ – Mick Raven
April 17, 2021
On April 10, Gao Fu, the head of the Chinese Center for Disease Control and Prevention, startled some in the government when he said at a medical conference that the efficacy of China’s vaccines was “not high” and that it could be improved by adjusting the number of doses, changing the amount of time between doses or mixing different types of vaccines.
He also stated that mRNA vaccines — the type made in the U.S. by Pfizer-BioNTech and Moderna — have achieved remarkable levels of immunity and that China should not overlook such technology. It was a scientific observation that immediately turned political. Gao was factually correct: China’s vaccines have a lower efficacy than those produced by Pfizer-BioNTech and Moderna.
In a rare admission of the weakness of Chinese coronavirus vaccines, the country’s top disease control official says their effectiveness is low and the government is considering mixing them to give them a boost.
But isn’t China Number 1? – Mick Raven
Biography of George Fu Gao Participant for Event 201 – The Gatekeepers Minion – Mick Raven
Just for the record – Mick Raven
Sep 24, 2020
Bill Gates recently stated that he views Pfizer (NYSE:PFE) as the leader in the coronavirus vaccine race. In a CNBC interview, he said, “The only vaccine that, if everything went perfectly, might seek the emergency use license by the end of October, would be Pfizer.”
The Gates Foundation also owns shares of the big drugmaker. However, this investment wasn’t initiated because of Pfizer’s coronavirus program. Actually, the foundation first bought a stake in Pfizer back in 2002 with the stated intention of “expand[ing] access to the pharmaceutical company’s all-in-one injectable contraceptive, Sayana Press, giving women in the developing world an affordable option.”
Gates is probably correct in assessing Pfizer as the coronavirus vaccine leader. The company expects to report initial results next month from a late-stage study of BNT162b2, the COVID-19 vaccine candidate that it’s developing with BioNTech (NASDAQ:BNTX). If all goes well, BNT162b2 could very well become the first coronavirus vaccine available to Americans.
It’s not surprising that the Bill & Melinda Gates Foundation also owns shares of BioNTech. Again, though, the nonprofit foundation didn’t invest in the German biotech stock because of its coronavirus program.
The Gates Foundation first bought a position in BioNTech in September 2019, well before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million. The foundation’s goal with this investment was to work with BioNTech to develop vaccines and immunotherapies for preventing HIV and tuberculosis (TB) infection.
BioNTech began developing its BNT162 COVID-19 vaccine program earlier this year. It had already made significant progress with this program when it announced a partnership with Pfizer in March.
In January 2016, we entered a global health project framework agreement with the Bill & Melinda Gates Foundation to advance mRNA-based development projects for various infectious diseases.
The Bill & Melinda Gates Foundation has committed up to $20.0 million in grant funding to support our initial project related to the evaluation of antibody combinations in a preclinical setting as well as the conduct of a first-in-human Phase 1 clinical trial of a potential mRNA medicine to help prevent human immunodeficiency virus, or HIV, infections.
Follow-on projects which could bring total potential funding under the framework agreement up to $100.0 million (including the HIV antibody project) to support the development of additional mRNA-based projects for various infectious diseases can be proposed and approved until the sixth anniversary of the framework agreement, subject to the terms of the framework agreement, including our obligation to grant to the Bill &Melinda Gates Foundation certain non-exclusive licenses.